Loading the session
Loading the session
Loading instrument
$130.34
+0.00%Delayed · Pre-marketDelayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 14:59 IST · A quote does not mean the product is available to trade on your account.
Opens 8:00 pm IST
Opens 8:00 pm IST
Opens 8:00 pm IST
In brief
Questions investors ask
Quotes run fifteen minutes behind.
1 month: +18.8% (SPY −1.6%, XLV +13.5%). 3 months: +55.9% (SPY −0.4%, XLV +15.5%). 1 year: +91.5% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: HALO, SPY and XLV · as of 4 Nov 2026
Closed at $130.34 on 4 Nov 2026: 2.7% below the 52-week high of $134.00 (30 Oct 2026) and 112.9% above the low of $61.23 (11 Dec 2025).
Daily price bars, split-adjusted · as of 4 Nov 2026
13.7M shares were sold short at the 15 Oct 2026 settlement, 12.0% of the 113.5M shares outstanding; covering them would take 6.2 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
The 4 Nov 2026 close of $130.34 was 13.4% above its 50-day average ($114.94) and 54.7% above its 200-day average ($84.24). It has closed above the 200-day for 95 sessions, since 23 Jun 2026. The 50-day average crossed above the 200-day on 6 Jul 2026, 86 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
The 14-session relative strength index closed at 72.8 on 4 Nov 2026, its 15th session at 70 or above. By convention a reading of 70 or above is called overbought and 30 or below oversold.
Daily closes, split-adjusted; Wilder's 14-session RSI · as of 4 Nov 2026
Price return, split-adjusted
At the 4 Nov 2026 close
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally.
August 7, 2026
+20.24%May 13, 2025
−24.56%May 7, 2025
+18.12%